Evidence map›Paper›PMID 35628545›Full record

ReviewInternational journal of molecular sciences2022

Exploration of Multiverse Activities of Endocannabinoids in Biological Systems.

Tapan Behl, Rashita Makkar, Aayush Sehgal, Sukhbir Singh, Hafiz A Makeen, Mohammed Albratty, Hassan A Alhazmi, Abdulkarim M Meraya, Simona Bungau

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Cys-loop receptors on cannabinoids: All high?Frontiers in physiology · 2022
    Pooled it
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. The Endocannabinoid System and Physical Exercise.International journal of molecular sciences · 2023
    Review
  9. Should oncologists trust cannabinoids?Frontiers in pharmacology · 2023
    Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 3 countries.

Tapan BehlChitkara College of Pharmacy, Chitkara University, Rajpura 140401, India.
Rashita MakkarChitkara College of Pharmacy, Chitkara University, Rajpura 140401, India.
Aayush SehgalChitkara College of Pharmacy, Chitkara University, Rajpura 140401, India.
Sukhbir SinghChitkara College of Pharmacy, Chitkara University, Rajpura 140401, India.
Hafiz A MakeenPharmacy Practice Research Unit, Clinical Pharmacy Department of College of Pharmacy, Jazan University, Jazan 45142, Saudi Arabia.ORCID 0000-0002-1078-2478
Mohammed AlbrattyDepartment of Pharmaceutical Chemistry and Pharmacognosy, College of Pharmacy, Jazan University, Jazan 45142, Saudi Arabia.
Hassan A AlhazmiDepartment of Pharmaceutcal Chemistry, College of Pharmacy, Jazan University, Jazan 45142, Saudi Arabia.
Abdulkarim M MerayaPharmacy Practice Research Unit, Clinical Pharmacy Department of College of Pharmacy, Jazan University, Jazan 45142, Saudi Arabia.ORCID 0000-0002-6876-7270
Simona BungauDepartment of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea, 410028 Oradea, Romania.ORCID 0000-0003-3236-1292
Chitkara University · INJazan University · SAUniversity of Oradea · RO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over the last 25 years, the human endocannabinoid system (ECS) has come into the limelight as an imperative neuro-modulatory system. It is mainly comprised of endogenous cannabinoid (endocannabinoid), cannabinoid receptors and the associated enzymes accountable for its synthesis and deterioration. The ECS plays a proven role in the management of several neurological, cardiovascular, immunological, and other relevant chronic conditions. Endocannabinoid or endogenous cannabinoid are endogenous lipid molecules which connect with cannabinoid receptors and impose a fashionable impact on the behavior and physiological processes of the individual. Arachidonoyl ethanolamide or Anandamide and 2-arachidonoyl glycerol or 2-AG were the endocannabinoid molecules that were first characterized and discovered. The presence of lipid membranes in the precursor molecules is the characteristic feature of endocannabinoids. The endocannabinoids are released upon rapid enzymatic reactions into the extracellular space via activation through G-protein coupled receptors, which is contradictory to other neurotransmitter that are synthesized beforehand, and stock up into the synaptic vesicles. The current review highlights the functioning, synthesis, and degradation of endocannabinoid, and explains its functioning in biological systems.

Indexed as

CannabinoidsEndocannabinoidsCannabinoid Receptor ModulatorsHumansReceptors, CannabinoidReceptors, G-Protein-CoupledCannabinoid Receptor ModulatorsCannabinoidsEndocannabinoidsReceptors, CannabinoidReceptors, G-Protein-Coupledcardiovascularendocannabinoidgastrointestinalimmunologicalneurotransmitterreceptor

Identifiers

PMID35628545
PMCPMC9147046
OpenAlexW4280618326

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.